Category RESEARCH

Response Pharmaceuticals

Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 for Long-Term Post-GLP-1 Weight Management

Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for…

Read MoreResponse Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 for Long-Term Post-GLP-1 Weight Management
Progeria

Progeria Research Foundation and Forge Biologics Partner to Strengthen Gene Therapy Development for Children

The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing…

Read MoreProgeria Research Foundation and Forge Biologics Partner to Strengthen Gene Therapy Development for Children